In addition, we predicted the sensitivity of common anti-cancer drugs on prognostic signature, including CCR5 (Fig. 6C), HMOX1 (Fig. 6D), CTSC (Fig. 6E), CD5 (Fig. 6F), BCL3 (Fig. 6G), CDH1 (Fig. 6H), TYROBP and CD38 (Fig. 6I). This evidence concerns the gene CD38 and cancer.